Jeffrey Horowitz is a Nephrology physician. ClinicalTrials.gov lists 17 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1030 President Ave
Fall River, MA 027205923
Telephone
508-235-6427Registry record last updated 27 Jun 2016.
Clinical trials
- Metabolic Adaptations to Weight Loss With and Without Exercise
Sponsor: University of Michigan
- Comparing the Effects of Exercise on the Structure and Function of Fat Tissue
Sponsor: University of Michigan
- Exercise Effects on Adipose Tissue Structure and Function
Sponsor: University of Michigan
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
66.2%Statin19%Atorvastatin Calcium48%Simvastatin33%Rosuvastatin Calcium19%Part D≥27 patientsACE inhibitor8.6%Lisinopril78%Lisinopril-Hydrochlorothiazide23%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
10.9%Proton pump inhibitor5.1%Omeprazole100%Part D≥18 patientsBiguanide (metformin)3.3%Metformin Hcl100%Part D≥11 patients+ 2 more classes in this area
Nervous system
5.8%Benzodiazepine2.9%Lorazepam52%Alprazolam48%Part D<11 patientsgamma-Aminobutyric Acid A Receptor Positive Modulator1.6%Zolpidem Tartrate100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”